Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FABP7 | O15540 | 2/20 | 0.59 |
| ▸ | FABP5 | Q01469 | 2/20 | 0.59 |
| ▸ | FABP3 | P05413 | 1/20 | 0.59 |
| ▸ | CRBN | Q96SW2 | 3/20 | 0.56 |
| ▸ | EIF2AK2 | P19525 | 1/20 | 0.45 |
| ▸ | RXRA | P19793 | 1/20 | 0.43 |
| ▸ | RXRB | P28702 | 1/20 | 0.43 |
| ▸ | TDP2 | O95551 | 5/20 | 0.43 |
| ▸ | BRD4 | O60885 | 1/20 | 0.42 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.42 |
| ▸ | PGR | P06401 | 2/20 | 0.42 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.40 |
| ▸ | CMA1 | P23946 | 2/20 | 0.40 |
| ▸ | AHR | P35869 | 2/20 | 0.40 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.40 |
| ▸ | CACNG8 | Q8WXS5 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24314011 | 0.89 | FABP7 (0.48) | FABP7FABP5FABP3CRBNRXRA | |
| SCHEMBL26794004 | 0.84 | FABP7 (0.62) | FABP7FABP5FABP3CRBNEIF2AK2 | |
| SCHEMBL24314052 | 0.82 | CYP11B1 (0.52) | FABP7FABP5FABP3CRBNPGR | |
| SCHEMBL4406856 | 0.81 | CRBN (0.57) | FABP7FABP5FABP3CRBNEIF2AK2 | |
| SCHEMBL4409546 | 0.78 | CRBN (0.54) | FABP7FABP5FABP3CRBNEIF2AK2 | |
| SCHEMBL7182961 | 0.77 | RXRA (0.58) | FABP7FABP5FABP3RXRARXRB | |
| SCHEMBL26793073 | 0.77 | CYP11B1 (0.50) | FABP7FABP5FABP3RXRARXRB | |
| SCHEMBL26793066 | 0.76 | MAPT (0.57) | RXRARXRB | |
| SCHEMBL24314053 | 0.76 | FABP7 (0.53) | FABP7FABP5FABP3CRBNEIF2AK2 | |
| SCHEMBL4467581 | 0.76 | CRBN (0.57) | FABP7FABP5FABP3CRBNEIF2AK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230365488-A1 | TRUXILLIC ACID MONOESTER-DERIVATIVES AS SELECTIVE FABP5 INHIBITORS AND PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) | 2023-11-16 | — | — | US | disclosed |
| WO-2022076820-A1 | TRUXILLIC ACID MONOESTER-DERIVATIVES AS SELECTIVE FABP5 INHIBITORS AND PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) | 2022-04-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230365488-A1 | TRUXILLIC ACID MONOESTER-DERIVATIVES AS SELECTIVE FABP5 INHIBITORS AND PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | FABP5, FABP1, FABP4 | FABP7 7/4885FABP5 1/4885FABP3 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.